# Guideline for the diagnosis and treatment of chronic myeloid leukemia in China (2025)

## TL;DR

The 2025 CML treatment guidelines in China update recommendations based on recent advances, including new drugs and personalized treatment strategies.

## Contribution

The guidelines introduce new TKI drugs and a Chinese-specific treatment failure prediction model, emphasizing individualized treatment and dose optimization.

## Key findings

- New TKI drugs like Asciminib and Olverembatinib are recommended for CML treatment.
- A Chinese-derived TKI treatment failure prediction model is introduced for prognosis.
- Dose optimization of TKI is recommended based on efficacy and safety considerations.

## Abstract

2025年版慢性髓细胞性白血病（CML）中国诊断与治疗指南在2020年版基础上，结合近5年来CML诊疗领域进展进行修订。参照2022国际共识分类（ICC）修订分期标准，明确CML急淋变中淋巴母细胞阈值。慢性期患者预后分层推荐ELTS评分系统，同时推荐源自中国多中心数据的酪氨酸激酶抑制剂（TKI）治疗失败预测模型，兼顾遗传学、分子学异常的预后意义。治疗药物新增阿思尼布、奥雷巴替尼、泊那替尼，阐述一线及后线治疗的决策原则。里程碑反应对后续治疗策略调整具有指导意义，但强调应个体化解读分子里程碑反应。首次提出在结合疗效和安全性基础上进行TKI剂量优化；无治疗持续缓解实施标准及停药后监测、生育相关问题有所调整，旨在保证疗效基础上，最大限度减少不良反应、改善生活质量。异基因造血干细胞移植依然是多种TKI耐药/不耐受以及进展期患者的根治性手段。